Sensus Healthcare Appoints Eric Sachetta as Director

Sensus Healthcare ( (SRTS) ) has shared an announcement.

On November 10, 2025, Sensus Healthcare appointed Eric Sachetta as a Class II director, filling the vacancy left by the late William McCall. Mr. Sachetta, a seasoned financial executive and Chief Wealth Services Officer at Sachetta, LLC, brings a wealth of experience in organizational growth and financial planning. His appointment is expected to enhance Sensus Healthcare’s strategic growth and operational excellence, aligning with the company’s mission to expand its SRT technology and global vision. The announcement was made public on November 12, 2025.

The most recent analyst rating on (SRTS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Sensus Healthcare stock, see the SRTS Stock Forecast page.

Spark’s Take on SRTS Stock

According to Spark, TipRanks’ AI Analyst, SRTS is a Neutral.

Sensus Healthcare’s strong financial performance and promising future growth prospects are offset by current cash flow challenges and valuation concerns. The technical indicators suggest potential short-term overbought conditions, while the earnings call provides a mixed outlook with both opportunities and risks.

To see Spark’s full report on SRTS stock, click here.

More about Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company that specializes in non-invasive and minimally-invasive treatments for skin conditions, including skin cancer and keloids. The company is known for its superficial radiotherapy (SRT and IG-SRT) technology, which provides effective and patient-centric treatment solutions in radiation oncology.

Average Trading Volume: 111,097

Technical Sentiment Signal: Hold

Current Market Cap: $75.62M

See more insights into SRTS stock on TipRanks’ Stock Analysis page.